Last reviewed · How we verify

A+C Vaccine — Competitive Intelligence Brief

A+C Vaccine (A+C Vaccine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

A+C Vaccine (A+C Vaccine) — Jiangsu Province Centers for Disease Control and Prevention. A+C Vaccine is a combined meningococcal vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
A+C Vaccine TARGET A+C Vaccine Jiangsu Province Centers for Disease Control and Prevention marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule
MCV-AC Vaccine Group MCV-AC Vaccine Group Beijing Minhai Biotechnology Co., Ltd phase 3 Conjugate vaccine Neisseria meningitidis serogroups A and C polysaccharide capsules
A+C Meningococcal Polysaccharide Vaccine A+C Meningococcal Polysaccharide Vaccine Hualan Biological Engineering, Inc. phase 3 Polysaccharide vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule
Meningococcal A+C vaccine Meningococcal A+C vaccine Sanofi Pasteur, a Sanofi Company marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C capsular polysaccharides
Meningococcal (vaccine) Meningococcal (vaccine) GlaxoSmithKline marketed Bacterial polysaccharide conjugate vaccine Neisseria meningitidis capsular polysaccharides and outer membrane proteins
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine Meningococcal ACYW135 Polysaccharide Conjugate Vaccine Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd phase 3 Polysaccharide conjugate vaccine Meningococcal serogroup A, C, Y, and W-135 polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polysaccharide conjugate vaccine class)

  1. Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · 1 drug in this class
  2. Jiangsu Province Centers for Disease Control and Prevention · 1 drug in this class
  3. Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A+C Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/a-c-vaccine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing